WST's Q4 Earnings & Sales Beat, SmartDose Sale by Mid-2026, Stock Up

robot
Abstract generation in progress

West Pharmaceutical Services (WST) reported a strong fourth quarter and full-year 2025, with earnings and sales surpassing analyst expectations. The company also announced plans to sell its SmartDose 3.5ml product to AbbVie by mid-2026 and provided optimistic guidance for 2026, driven by robust performance in its Proprietary Products segment and HVP growth. The stock rose following the announcement, reflecting investor confidence in its strategic execution and future outlook.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)